Zevra Therapeutics Inc
ZVRAHealthcare|Biotechnology|USA
$13.34
-0.59 (-4.23%)
Tangible Book
$3.30
Analyst Estimates
annual
{
"date": [
"202612",
"202712",
"202812",
"202912",
"203012"
],
"revenue_estimate": [
146.82,
180.3,
259.9,
322.85,
387.05
],
"ebit_estimate": [
71.09,
64.22,
135.51,
188.61,
247.49
],
"ebitda_estimate": [
79.4,
51.8,
109.8,
172.6,
216.5
],
"net_income_estimate": [
63.84,
57.41,
123.75,
169.31,
216.73
],
"per_share_eps_estimate": [
1.03,
0.9,
1.98,
2.67,
3.38
],
"eps_nri_estimate": [
1.03,
0.88,
1.93,
2.67,
3.38
],
"dividend_estimate": [
null,
null,
null,
null,
null
],
"book_value_per_share_estimate": [
3.52,
4.48,
6.06,
8.34,
10.95
],
"pretax_income_estimate": [
78.36,
76.05,
144.38,
198.62,
260.12
],
"operating_cash_flow_per_share_estimate": [
0.81,
0.92,
1.5,
2.36,
2.68
],
"roa_estimate": [
null,
null,
null,
null,
null
],
"roe_estimate": [
0.41,
21,
28.8,
30.7,
26.7
],
"gross_margin_estimate": [
94.28,
94.12,
94.13,
93.5,
93.5
],
"operating_cash_flow_estimate": [
48.79,
55.41,
90.35,
142.14,
161.42
],
"pettm_estimate": [
13,
14.83,
6.72,
5,
3.94
],
"long_term_growth_rate_mean": 0,
"long_term_revenue_growth_rate_mean": "33.41",
"future_per_share_eps_estimate_growth": null,
"future_eps_nri_estimate_growth": null,
"future_revenue_estimate_growth": 33.41,
"future_ebit_estimate_growth": null,
"future_ebitda_estimate_growth": null,
"future_dividend_estimate_growth": null,
"future_net_income_estimate_growth": null,
"future_pretax_income_estimate_growth": 16.19,
"future_book_value_per_share_estimate_growth": 30.27,
"future_roa_estimate_growth": null,
"future_roe_estimate_growth": null,
"future_gross_margin_estimate_growth": 4.63,
"future_operating_cash_flow_per_share_estimate_growth": null
}
quarterly
{
"date": [
"202606",
"202609",
"202612",
"202703",
"202706",
"202709",
"202712",
"202803"
],
"revenue_estimate": [
34.15,
36.48,
40.09,
37.53,
40.77,
42.47,
44.47,
51.69
],
"ebit_estimate": [
6.98,
8.74,
11.8,
5.75,
7.6,
6.65,
7.85,
null
],
"ebitda_estimate": [
6.6,
8.4,
11.9,
14.2,
13.9,
12,
11.7,
null
],
"net_income_estimate": [
7.48,
9.03,
11.93,
8.15,
10.1,
9.15,
10.5,
null
],
"per_share_eps_estimate": [
0.11,
0.15,
0.18,
0.14,
0.18,
0.19,
0.21,
null
],
"eps_nri_estimate": [
0.11,
0.13,
0.17,
0.14,
0.18,
0.19,
0.21,
0.32
],
"dividend_estimate": [
null,
null,
null,
null,
null,
null,
null,
null
],
"book_value_per_share_estimate": [
3.12,
3.29,
3.51,
3.76,
4.01,
4.23,
4.45,
null
],
"pretax_income_estimate": [
8.42,
10.65,
14.39,
14.48,
16.17,
16.32,
17.62,
null
],
"operating_cash_flow_per_share_estimate": [
0.13,
0.18,
0.22,
0.09,
0.29,
0.27,
0.28,
null
],
"roa_estimate": [
null,
null,
null,
null,
null,
null,
null,
null
],
"roe_estimate": [
4.4,
5.1,
6.5,
6.7,
6.2,
5.2,
4.9,
null
],
"gross_margin_estimate": [
94.18,
94.18,
94.2,
94.4,
94.4,
94.4,
94.4,
null
],
"operating_cash_flow_estimate": [
7.83,
10.84,
13.25,
5.42,
17.47,
16.26,
16.86,
null
],
"pettm_estimate": [
23.23,
20.64,
19.21,
18.29,
null,
null,
null,
null
],
"long_term_growth_rate_mean": 0,
"long_term_revenue_growth_rate_mean": "33.41",
"future_per_share_eps_estimate_growth": null,
"future_eps_nri_estimate_growth": null,
"future_revenue_estimate_growth": 33.41,
"future_ebit_estimate_growth": null,
"future_ebitda_estimate_growth": null,
"future_dividend_estimate_growth": null,
"future_net_income_estimate_growth": null,
"future_pretax_income_estimate_growth": 16.19,
"future_book_value_per_share_estimate_growth": 30.27,
"future_roa_estimate_growth": null,
"future_roe_estimate_growth": null,
"future_gross_margin_estimate_growth": 4.63,
"future_operating_cash_flow_per_share_estimate_growth": null
}